SY-1425 Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
SY-1425 is being studied as a treatment for participants with a type of leukemia called acute
myeloid leukemia, or AML for short. SY-1425 is being studied as a treatment for participants
with AML whose cancer has a specific genetic abnormality characterized by the overexpression
of the retinoic acid receptor alpha (RARA) gene. This genetic profile is found in about 3 of
every 10 people with AML.
During the trial, SY-1425 will be given with 2 other drugs that are already used together to
treat people who have AML and who cannot start treatment with standard chemotherapy.